PreprintPDF Available

A Zero Carbohydrate, Carnivore Diet can Normalize Hydrogen Positive Small Intestinal Bacterial Overgrowth Lactulose Breath Tests: A Case Report

Authors:
Preprints and early-stage research may not have been peer reviewed yet.

Abstract

Background: Small intestinal bacterial overgrowth (SIBO) is a clinical condition characterized by an excessive bacterial growth in the small intestine. Clinical symptoms might be non-specific (dyspepsia, bloating or abdominal discomfort). Nevertheless, SIBO can cause severe malabsorption, serious malnutrition, immune reactions, and deficiency syndromes. This retrospective case report introduces six patients with positive lactulose hydrogen SIBO breath tests. The patients chose between different therapeutic options and willingly consented to a nutritional intervention, based on a zero carbohydrate, zero fibre, carnivore diet, extended over two to six weeks of time. The rationale for this dietary approach was based on the idea that opportunistic, carbohydrate favouring bacteria and methanogens proliferate in the small intestines if the natural barriers in the digestive tract have been weakened due to stress, illness, medication, etc. A zero carbohydrate, carnivore diet, consisting of animal fats and protein, could essentially eliminate these carbohydrate favouring bacteria through starvation while still providing plenty of both calories and nutrients. Methods: six patients from our functional medicine clinic followed a strict zero carb, zero fiber, carnivore diet for 2-6 weeks. A lactulose breath test was performed immediately before and after the dietary change as well as extensive medical testing. Results: five patients that followed the carnivore diet for four weeks or longer tested negative for SIBO, and the one patient that only endured the diet for two weeks had a near complete eradication of her hydrogen elevation. Methane values were generally low both before and after the dietary treatment, but there was a significant decrease in patients 3 and 5. Conclusions: The carbohydrate, zero fibre, carnivore diet shows great potential for being a readily available, cost-effective, and equally effective alternative treatment for SIBO. According to our observations it also results in better satisfaction after meals, decreases cravings for sweets and generate weight-loss in patients where it is needed.
Page 1/12
A Zero Carbohydrate, Carnivore Diet can Normalize
Hydrogen Positive Small Intestinal Bacterial
Overgrowth Lactulose Breath Tests: A Case Report
Peter Martin
FunMed Gothenburg Sweden
Martina Johansson ( martina.akj@gmail.com )
Institution for Medicine and health https://orcid.org/0000-0001-7031-2892
Annelie Ek
FunMed Gothenburg
Research article
Keywords: Zero carbohydrate, carnivore diet, small intestinal bacterial overgrowth, SIBO, lactulose hy-drogen
breath testing, nutritional intervention.
DOI: https://doi.org/10.21203/rs.3.rs-148500/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read
Full License
Page 2/12
Abstract
Background: Small intestinal bacterial overgrowth (SIBO) is a clinical condition characterized by an
excessive bacterial growth in the small intestine. Clinical symptoms might be non-specic (dyspepsia,
bloating or abdominal discomfort). Nevertheless, SIBO can cause severe malabsorption, serious
malnutrition, immune reactions, and deciency syndromes. This retrospective case report introduces six
patients with positive lactulose hydrogen SIBO breath tests. The patients chose between different
therapeutic options and willingly consented to a nutritional intervention, based on a zero carbohydrate, zero
bre, carnivore diet, extended over two to six weeks of time. The rationale for this dietary approach was
based on the idea that opportunistic, carbohydrate favouring bacteria and methanogens proliferate in the
small intestines if the natural barriers in the digestive tract have been weakened due to stress, illness,
medication, etc. A zero carbohydrate, carnivore diet, consisting of animal fats and protein, could essentially
eliminate these carbohydrate favouring bacteria through starvation while still providing plenty of both
calories and nutrients.
Methods: six patients from our functional medicine clinic followed a strict zero carb, zero ber, carnivore
diet for 2-6 weeks. A lactulose breath test was performed immediately before and after the dietary change
as well as extensive medical testing.
Results: ve patients that followed the carnivore diet for four weeks or longer tested negative for SIBO, and
the one patient that only endured the diet for two weeks had a near complete eradication of her hydrogen
elevation. Methane values were generally low both before and after the dietary treatment, but there was a
signicant decrease in patients 3 and 5.
Conclusions: The carbohydrate, zero bre, carnivore diet shows great potential for being a readily available,
cost-effective, and equally effective alternative treatment for SIBO. According to our observations it also
results in better satisfaction after meals, decreases cravings for sweets and generate weight-loss in patients
where it is needed.
Background
Small intestinal overgrowth (SIBO) is denoted as an increase in overall bacterial population in the small
intestine, particularly in types of bacteria not commonly found in that part of the digestive tract. There are
three different types of SIBO where some bacteria produce hydrogen, others methane and the third group
hydrogen sulphide.[1] Hydrogen- and methane producing bacteria are easily detected with a lactulose
breath test. The symptoms typically include gastrointestinal issues like diarrhoea, steatorrhea, chronic
abdominal pain, bloating, and atulence.[2] It is increasingly popular to treat these symptoms with dietary
changes; elemental diet as well as low FODMAP is continuously being used with a high success rate in
remission. Elemental diet is a mixture of pre-digested amino-acids, fats, sugars, and vitamins in liquid form,
while low FODMAP is a diet low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and
Polyols, as these nutrients are poorly absorbed and commonly cause gut issues.[3] Low FODMAP is not
relevant as a SIBO treatment, but rather to give some relief from IBS (irritable bowel syndrome). SIBO and
Page 3/12
IBS are oftentimes mentioned in conjunction, but they are not always dependent on each other. According to
studies SIBO is the most common cause of IBS, but not the one and only cause. Other explanations for IBS
could be, for example, celiac disease or dysbiosis in the colon.[4]
The main mechanisms restricting bacterial colonization in the upper gut are the gastric acid barrier and
mucosal and systemic immunity. When these mechanisms fail, bacterial overgrowth can develop.[5]
Another cause for bacterial overgrowth in the small intestine could be due to inecient migrating motor
complex (MMC). Bacteria, which normally should have been transported to the colon, remain in the small
intestine, and reproduce there.[6]
The functional medicine model of care provides an operating system that works to reverse illness, promote
health, and optimize function by addressing underlying causes, symptoms, and functional imbalances in
interconnected biological networks. [7] The functional medicine approach to SIBO includes treatment of
underlying disease, nutritional support, and broad-spectrum antibiotics. However, antibiotics increase the
risk of antibiotic resistance and undermine a healthy gut ora, thus compromising the entire immune
system.[8]
As an alternative approach the patients were recommended to follow a zero carbohydrate, zero bre,
carnivore diet for two to six weeks. The theory is that SIBO thrive on carbohydrates and bre and starve
when these macronutrients are eliminated. According to a study viewing Escherichia coli metabolism in the
gut, the bacteria grows best on sugars. [25]
The carnivore diet has gained popularity in recent years, as the extreme end of the spectrum of low
carbohydrate diets. The diet is commonly utilized by people with overly sensitive immune systems and
treatment resistant obesity. Even though there is evolutionary evidence for animal-based nutrition in our
species [9, 10], there are no published original research articles or clinical reports on the therapeutic effect of
a carnivore diet, and one reason for this might be the controversial status of an exclusively animal based
diet. However, this case report from our functional medicine clinic, is not about the long-term effect of this
diet, and our purpose is not to promote a zero carbohydrate, carnivore diet for any reason, but to present
evidence of its effectiveness as a cost effective, readily available, short-term nutritional therapy to
normalize a hydrogen positive result in the SIBO lactulose breath test.
Methods
This case report is a retrospective review of ongoing clinical work, with the SIBO breath tests recorded
between October 2018 to August 2020. All six subjects were regular patients at a functional medicine [7]
clinic (FunMed) in Gothenburg, Sweden, and followed the structured process used by this clinic. The
subjects consented to scientic publication of the collected data in writing. After a rst visit to an M.D. (Dr
Peter Martin) they all performed an extensive blood panel (Unilabs, Sweden), GI Effects comprehensive
stool test (Genova Diagnostics, UK), Nutrient and Toxic Element Prole (NutrEval, Genova Diagnostics, UK),
ImuPro IgG antibody screening for food intolerances (CTL & Ortholabor GmbH, Germany), and a SIBO
lactulose hydrogen/methane breath test (Biolab, UK). The SIBO breath test was performed before and
Page 4/12
directly after (on the last day of) the dietary change. No antibiotic drugs or antimicrobial agents were used
during the treatment period. There was no commercially available diagnostic tool for hydrogen sulphide
SIBO when these patients were treated.
The therapeutic diet
All patients were instructed to follow a strict zero carbohydrate, zero bre, carnivore diet for two to six
weeks. The diet was exclusively composed of animal fats and proteins: all types of meat, organ meats, sh,
poultry, tallow, lard, and eggs. No vegetables, vegetable oils or dairy products except for butter was included.
Extra intake of table salt was recommended to compensate for sodium loss. The patients could drink
coffee, tea, and water, but no sweetened beverages or diet sodas. No caloric limit or other restrictions were
implied, the patients were encouraged to eat as much and as often as they wanted.
Lactulose Hydrogen and Methane Breath Test
Breath samples (n=10) were collected using glass vacuum vials with rubber tops that was pushed on a
rubber-clad needle. Patients were instructed to, in the morning after a >12 hour overnight fast, breath into a
standardized plastic bag connected to the needle and sample their breath at t=0 min, and then ingest a
lactulose solution. Subsequent breath samples were collected at t= 20, 40, 60, 80, 100, 120, 140, 160 and
180 minutes. Preparation before the test is normally eating a zero carbohydrate, zero bre diet the day
before the test. The purpose for this is to starve the bacteria prior to the test to minimize ongoing gut
fermentation.[11] In our case, the strict diet was instead followed for two to six weeks.
The sample was sent to Biolab medical unit in England for analysis and measurement of hydrogen and
methane levels. Since lactulose unlike glucose is poorly absorbed in the intestines, but readily digested by
gas producing bacteria, this test makes it possible to detect bacterial overgrowth in the entire
gastrointestinal tract. A positive lactulose breath test was
dened as an increase of hydrogen at least 20 ppm (parts per million) above baseline within the rst 90
minutes, or if a hydrogen double peak was present, which is in line with our clinical experience reinforcing
the SIBO diagnosis.
NutrEval
Urine samples were sent to Genova diagnostics laboratories to measure organic acids, which indicates cell
functionality, nutrient balance, mitochondrial function, bacterial or fungus overgrowth and more. Blood
samples were analysed for content of minerals, toxic elements, glutathione, CoQ10, vitamin D and fatty
acids.
GI Effects Comprehensive stool test
Stool samples were sent to Genova diagnostics laboratories to analyse bacterial content in colon, digestion
of macronutrients, parasites, inammation, and more.
ImuPro IgG antibody test
Food intolerance test measuring IgG antibodies in blood for several foods. High levels of IgG antibodies
Page 5/12
indicate delayed allergic reaction to that specic kind of food. Blood samples were sent to CTL & Ortholabor
GmbH in Germany.
Blood tests
A comprehensive blood panel including kidney, thyroid and liver status, nutrients, lipid panel, CRP, insulin,
glucose and more. Unilabs test labs were used for these analyses.
Questionnaires
The patients also lled out the FunMed clinic standard questionnaires about their lifestyle and current
health status and went through the standard medical check-up. They all had individual health concerns that
were taken into consideration as well as monitored and investigated.
Results
Background data on all six patients are shown in Table1, while Table2 is displaying the individual
experiences of the carnivore diet intervention.
Figure 1 displays the results for the lactulose hydrogen/methane SIBO breath test for each patient before
and after dietary treatment. Note the variation in scale on the Y axis for patient 2 and patient 3. The ve
patients that followed the carnivore diet for four weeks or longer tested negative for SIBO, and the patient
that only endured the diet for two weeks had a near complete eradication of her hydrogen elevation.
Methane values were generally low both before and after the dietary treatment, but there was a signicant
decrease in patients 3 and 5.
Patient 2 and patient 4 followed the diet for four weeks whereas patient 3 followed it for two weeks, patient
5 for ve weeks and patient 1 and 6 for six weeks. Patient 3 was treated with antibiotics (Xifaxan 550mg
three times a day) for ve weeks prior to the carnivore experiment, without noticeable effect on the
hydrogen curve.
Table1.
This table presents an overview of the patient’s main concerns, nutrient deciencies, select lab results and
gastrointestinal status as well as their post-treatment SIBO test results.
Page 6/12
Subjects Main concerns Nutrient
deciencies
& select
other labs
Presence
of
hippuric
acid in
urine
Gastro-
intestinal
issues
E. coli
bacteria in
stool test
SIBO test
result after
diet
treatment
(weeks)
Pat.1
Female
22 y/o
Stubborn
fungal
infections and
rashes.
Magnesium,
potassium,
folate, B12.
Yes Gluten
sensitivity and
stomach
discomfort
High Negative
test (6
weeks)
Pat.2
Female
65 y/o
pre-diabetic,
over-weight,
hypertension,
Cushing’s
syndrome and
slight rosacea
tendencies.
Magnesium,
zinc, folate,
B12, glycine.
Elevated
pyroglutamic
acid and 5-
HIAA.
Yes Bloating,
stomach
aches.
Normal Negative
test
(4 weeks)
Pat.3
Female
46 y/o
Chronic
constipation,
high stress,
poor sleep, dry
skin, slight
rosacea
tendencies.
Magnesium,
potassium,
B2, B12,
glycine.
Elevated 5-
HIAA,
pyroglutamic
acid and 1-
methyl-
histidine.
Yes Chronic
constipation due
to slow bowel
movements
High Hydrogen
reduced
from
150ppm to
20ppm (2
weeks).
Methane
reduced
from 16 to
3ppm.
Pat.4
Female
48 y/o
Cravings,
fatigue, chronic
diarrhoea.
Primary
diagnosis is
Graves’
disease.
Magnesium,
zinc,
potassium,
vitamin D,
B1, B2, B6,
folate, B12.
Elevated 5-
HIAA,
pyroglutamic
acid and
carnosine.
No Chronic
diarrhoea Normal Negative
test (4
weeks)
Pat.5
Female
23 y/o
Fatigue, joint
pains, low
ferritin,
constipation,
OCD
Magnesium,
potassium,
ferritin, B6,
folate, B12.
Yes Constipation.
Possibly due to
poor thyroid
function.
Normal Negative
test
(5
weeks)
Methane
reduced
from 5 − 
0ppm.
Page 7/12
Subjects Main concerns Nutrient
deciencies
& select
other labs
Presence
of
hippuric
acid in
urine
Gastro-
intestinal
issues
E. coli
bacteria in
stool test
SIBO test
result after
diet
treatment
(weeks)
Pat.6
Female
49 y/o
Hypothyroidism
(Hashimotos),
rosacea,
endometriosis.
Magnesium,
B1, B2, B3,
B6, biotin,
folate, B12,
glycine.
Elevated
arabinose, 5-
HIAA,
pyroglutamic
acid and 1-
methyl-
histidine.
Yes Slow bowel
movements.
Due to
hypothyroidism?
Normal Negative
test (6
weeks)
Table2.
This table provides a brief overview of the individual experience for each patient.
Subjects Experiences Physical side effects Weight loss &
labs
Pat.1
Female
22 y/o
Enjoyed the diet and continued with a
low carbohydrate, low bre diet. Rapid weight loss Approx. 2kg,
folate 8nM
(did not eat
liver)
Pat.2
Female
65 y/o
Found it boring without vegetables and
had cravings for sweets. Less bloating.
Better sleep.
None 2kg
CRP down from
5 to 0,77,
HbA1c 60 to 51
Pat.3
Female
46 y/o
Experienced better energy and found
the diet tolerable. Body aches during the rst
week. 2kg during
carnivore diet,
11kg in total.
Pat.4
Female
48 y/o
Had a dicult adaption period,
otherwise tolerable. Tongue coating
disappeared.
diarrhoea, low energy during
the rst 2 weeks. Weight after
carnivore diet
not recorded.
Pat.5
Female
23 y/o
Enjoyed the diet. Less headache, joint
pain and stomach pain. None Same weight
as before
Pat.6
Female
49 y/o
Enjoyed the diet and continued with a
low carbohydrate, low bre diet. Hair
and nail quality increased.
Adjustment problems with
diarrhoea, rapid weight loss
during the rst week.
Approx. 10kg
Page 8/12
Exploratory Analyses
With an extensive amount of laboratory analyses available for each patient we checked for other interesting
ndings besides SIBO test results. According to the measurements there were no distinct evidence from
stool tests that SIBO caused unsatisfactory digestion of fat or proteins, even though most patients had self-
reported digestive issues. All patients had nutritional deciencies according to the extensive blood and urine
organic acids panels. Hippuric acid was present in the urine of all patients, except for one, and may be a
marker of gut bacteria overgrowth [12], even though no clear reference interval seems to be acknowledged.
The comprehensive stool test revealed elevated E.coli content in the colon in two of the patients, but no
other SIBO-related bacteria or bacterial or parasite infections were found. E. coli is one of the major players
associated with hydrogen dominant SIBO.[13]
Limitations
The lactulose breath test has been shown to have a higher sensitivity but a lower specicity, as compared to
the glucose breath test.[14, 15] We argue that the test with the higher sensitivity (lactulose breath test) is a
better choice for SIBO detection in a functional medicine clinic, especially when the short term dietary
treatment can be considered having few side effects.[16, 17] However, because of a lot of contradicting
reports about the effectiveness of the various types of SIBO testing techniques[18], this may be a weakness
in this report.
This was an unsupervised dietary intervention. Even though the patients were highly motivated it is
impossible to verify to what degree they were following the diet. Further, even though SIBO tests were
adequately timed before and after the diet intervention, all additional tests were spread out rather than
perfectly timed before and after the carnivore weeks.
All subjects were females, reecting that 70% of our patients are female. Commercially available diagnostic
tools for hydrogen sulphide SIBO was not present before October 2020.
Discussion
This retrospective case report from a functional medicine [7] clinic, is to the best of our knowledge the rst
published evidence that a short term exclusively animal based, zero carbohydrate carnivore diet can
normalize hydrogen positive lactulose SIBO breath tests. The patients chose to eat this therapeutic diet
from two to six weeks of time. The rationale for this dietary approach was the fact that the most clinically
successful diet for the treatment of SIBO published so far, the elemental diet, can result in 80–84%
remission of SIBO in only 2–3 weeks of treatment. [19] As shown in this paper, our clinical experience with a
zero-carb carnivore diet reveals an equally high success rate, but with the added benet of being more
palatable and more suitable for hypoglycaemic patients and patients with insulin resistance. A carnivore
diet is cost effective, readily available, and according to our observations results in better satisfaction after
meals and decreases cravings for sweets.
Page 9/12
Conventionally, a double peak in lactulose hydrogen breath test (one due to SIBO and the other from colonic
fermentation) is considered diagnostic of SIBO. Pimentel et al suggested that a rise in breath hydrogen
20ppm above basal levels within 90 minutes after ingestion of lactulose should be considered a positive
test.[20] Following this rationale in conjunction with the fact that all patients had gastrointestinal issues
and nutritional deciencies [21] it is likely that the patients indeed suffered from SIBO. However, patient 3
and 5 lacked a distinct double peak while simultaneously suffering from chronic constipation. We
acknowledge this as an interesting observation as some data also suggest that patients with constipation
have different breath test results than patients with IBS or diarrhoea.[22] Patients 3 and 5 also had the most
prominent reductions in methane gas from the diet intervention which may lead to less constipation.
According to our observations as well as the patients’ own experiences, the diet intervention resulted in
resolution of gut issues. Several patients experienced additional benets such as weight loss and increased
well-being, even though the rst week of a zero-carbohydrate diet can be tough for anyone not used to
limiting their carbohydrate intake. In comparison with the elemental diet, the carnivore diet provides more
satiety, biocompatible nutrients, and general enjoyment as there is no caloric restriction and the patients’
have freedom to choose their daily food intake as long as they follow the guidelines. This makes the diet
more endurable than the elemental diet while seemingly being just as effective. Unfortunately, meat, organ
meats and animal fat has gotten a bad rap due to weak epidemiological studies linking these food products
to heart disease and cancer. [23] However, it is probably safe to say that very few of the heavy meat eaters
in these studies, ate a zero carbohydrate, zero bre, carnivore diet. Much more factors come into play in the
development of lifestyle diseases such as smoking habits, alcohol intake, training frequency and overall
quality of life. Although small case reports [24] has been published, no large, controlled studies have been
made on the safety of following a carnivore diet for longer periods of time. In the present material, no
serious side-effects were detected in following the diet for a few weeks of time as an elimination diet or for
SIBO eradication.
Conclusion
The present case report of six patients from our functional medicine clinic shows for the rst time (Fig.1)
that a zero carbohydrate, zero bre, carnivore diet, have the potential to normalize hydrogen positive SIBO
breath tests in a comparable manner to the elemental diet, but with the added benet of being more
palatable and easier to endure. The presented data points to a short-term carnivore diet as an evolutionarily
sound, cost effective and readily available addition to our clinical therapeutic options for SIBO, which merits
further evaluation in larger studies.
Abbreviations
SIBO Small Intestinal Bacterial Overgrowth
FODMAP Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols
IBS Irritable Bowel Syndrome
Page 10/12
MMC Migrating Motor Complex
IgG Immunoglobulins G
5-HIAA 5-Hydroxyindoleacetic acid
OCD Obsessive Compulsive Disorder
CRP C-reactive protein
Declarations
Ethics approval and consent to participate
Not applicable
Consent for publication
This case report is a retrospective review of ongoing clinical work. All patients were regular patients at the
functional medicine clinic FunMed in Gothenburg, Sweden, and consented to scientic publication of the
collected data in writing.
Availability of data and material
Not applicable
Competing interests
The authors declare no conict of interest.
Funding
This research received no external funding.
Author Contributions
PM was the clinician in charge of this study. He managed the patients, the test interpretation, and their
experimental dietary intervention, as well as contributed as an author. MJ and AE performed article research
and article writing. All authors reviewed and approved of the manuscript.
Acknowledgements
We thank the patients for allowing us to share their details and for their bravery in trying a highly
unconventional diet.
References
1. Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, … & Kopacova M. Small intestinal
bacterial overgrowth syndrome. World journal of gastroenterology: WJG. 2010;16(24):2978.
2. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable
bowel syndrome-related symptoms: experience with Rifaximin. World journal of gastroenterology: WJG.
Page 11/12
2009;15(21):2628.
3. Rao SS, Bhagatwala J. (2019). Small intestinal bacterial overgrowth: Clinical features and therapeutic
management. Clinical and translational gastroenterology, 10(10).
4. Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a
bridge between functional organic dichotomy. Gut Liver. 2017;11(2):196.
5. Quigley EM. The spectrum of small intestinal bacterial overgrowth (SIBO). Current Gastroenterology
Reports. 2019;21(1):3.
6. Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its
role in health and disease. Nature reviews Gastroenterology hepatology. 2012;9(5):271.
7. Beidelschies M, Alejandro-Rodriguez M, Ji X, Lapin B, Hanaway P, Rothberg MB. Association of the
functional medicine model of care with patient-reported health-related quality-of-life outcomes. JAMA
network open. 2019;2(10):e1914017–7.
8. Willmann M, Vehreschild MJ, Biehl LM, Vogel W, Dörfel D, Hamprecht A, … Peter S. Distinct impact of
antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study. BMC Biol.
2019;17(1):1–18.
9. Agam A, Barkai R. (2018). Elephant and mammoth hunting during the Paleolithic: a review of the
relevant archaeological, ethnographic and ethno-historical records. Quaternary, 1(1).
10. Wißing C, Rougier H, Baumann C, Comeyne A, Crevecoeur I, Drucker DG, … Matthies T. Stable isotopes
reveal patterns of diet and mobility in the last Neandertals and rst modern humans in Europe.
Scientic reports. 2019;9(1):1–12.
11. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Pimentel M. Hydrogen and methane-based
breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol.
2017;112(5):775.
12. Calvani RICC, Miccheli A, Capuani G, Miccheli AT, Puccetti C, Delni M, … & Mingrone G. Gut
microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int J Obes.
2010;34(6):1095–8.
13. Gabriela Leite W, Morales S, Weitsman S, Celly G, Parodi R, Mathur GM, Barlow R, Sedighi., Maria Jesus
Villanueva Millan, Ali Rezaie, Mark Pimentel. (July 9, 2020). The duodenal microbiome is altered in
small intestinal bacterial overgrowth. PLoS ONE 15(7): e0234906.
14. Ghoshal UC. How to interpret hydrogen breath tests. Journal of Neurogastroenterology motility.
2011;17(3):312.
15. Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55(3):297–303.
16. Riordan SM, McIver CJ, Walker BM, Duncombe VM, Bolin TD, Thomas MC. (1996). The lactulose breath
hydrogen test and small intestinal bacterial overgrowth. American Journal of Gastroenterology
(Springer Nature), 91(9).
17. Ruscio M. (2019). Is SIBO A Real Condition?. Alternative Therapies in Health & Medicine, 25(5).
18. Rana SV, Sharma S, Kaur J, Sinha SK, Singh K. Comparison of lactulose and glucose breath test for
diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion.
Page 12/12
2012;85(3):243–7.
19. Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly
effective in normalizing the lactulose breath test. Digestive diseases sciences. 2004;49(1):73–7.
20. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms
of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–6.
21. Quigley EM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial
overgrowth: expert review. Gastroenterology. 2020;159(4):1526–32.
22. Soares ACF, Lederman HM, Fagundes-Neto U, de Morais MB. Breath hydrogen test after a bean meal
demonstrates delayed oro-cecal transit time in children with chronic constipation. J Pediatr
Gastroenterol Nutr. 2005;41(2):221–4.
23. Vernooij, R. W., Zeraatkar, D., Han, M. A., El Dib, R., Zworth, M., Milio, K., … Swierz,M. J. (2019). Patterns
of red and processed meat consumption and risk for cardiometabolic and cancer outcomes: a
systematic review and meta-analysis of cohort studies. Annals of internal medicine, 171(10), 732–741.
24. Tolstoi E. The effect of an exclusive meat diet lasting one year on the carbohydrate tolerance of two
normal men. Incorporated: Waverly Press; 1929.
25. Conway T, Cohen PS. Commensal and Pathogenic Escherichia coli Metabolism in the Gut. Microbiol
Spectr. 2015 Jun;3(3):10.
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Small intestinal bacterial overgrowth (SIBO) is highly prevalent and is associated with numerous gastrointestinal disorders, but the microbes involved remain poorly defined. Moreover, existing studies of microbiome alterations in SIBO have utilized stool samples, which are not representative of the entire gastrointestinal tract. Therefore, we aimed to determine and compare the duodenal microbiome composition in SIBO and non-SIBO subjects, using duodenal aspirates from subjects undergoing standard-of-care esophagogastroduodenoscopy without colon preparation. Using the recently-redefined cutoff for SIBO of >103 colony forming units per milliliter (CFU/mL), 42 SIBO and 98 non-SIBO subjects were identified. Duodenal samples from SIBO subjects had 4x103-fold higher counts than non-SIBO subjects when plated on MacConkey agar (P
Article
Full-text available
Importance The incidence of chronic disease is increasing along with health care–related costs. The functional medicine model of care provides a unique operating system to reverse illness, promote health, and optimize function. The association between this model of care and patient’s health-related quality of life (HRQoL) is unknown. Objective To assess the association between functional medicine and patient-reported HRQoL using Patient-Reported Outcome Measurement Information System (PROMIS) global health measures. Design, Setting, and Participants A retrospective cohort study was performed to compare 7252 patients aged 18 years or older treated in a functional medicine setting with propensity score (PS)–matched patients in a primary care setting. Sensitivity analyses assessed improvement limited to patients seen at both 6 and 12 months. The study included patients who visited the Cleveland Clinic Center for Functional Medicine or a Cleveland Clinic family health center between April 1, 2015, and March 1, 2017. Main Outcomes and Measures The primary outcome was change in PROMIS Global Physical Health (GPH) at 6 months. Secondary outcomes included PROMIS Global Mental Health (GMH) at 6 months and PROMIS GPH and GMH at 12 months. The PROMIS GPH and GMH scores were transformed to a T-score from 0 to 100 with a mean of 50. Higher scores indicate a better health-related quality of life. Results Of the 7252 patients (functional medicine center: 1595; family health center: 5657), 4780 (65.9%) were women; mean (SD) age was 54.1 (16.0) years. At 6 months, functional medicine patients exhibited significantly larger improvements in PROMIS GPH T-score points than were seen in patients treated at a family health center (mean [SD] change, functional medicine center: 1.59 [6.29] vs family health center: 0.33 [6.09], P = .004 in 398 PS-matched pairs). At 12 months, functional medicine patients showed improvement similar to that observed at 6 months; however, comparisons with patients seen at the family health center were not significant. Patients in the functional medicine center with data at both 6 and 12 months demonstrated improvements in PROMIS GPH (mean [SD], 2.61 [6.53]) that were significantly larger compared with patients seen at a family health center (mean [SD], 0.25 [6.54]) (P = .02 in 91 PS-matched pairs). Conclusions and Relevance In this study, the functional medicine model of care demonstrated beneficial and sustainable associations with patient-reported HRQoL. Prospective studies are warranted to confirm these findings.
Article
Full-text available
Background: Studying dietary patterns may provide insights into the potential effects of red and processed meat on health outcomes. Purpose: To evaluate the effect of dietary patterns, including different amounts of red or processed meat, on all-cause mortality, cardiometabolic outcomes, and cancer incidence and mortality. Data Sources: Systematic search of MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Web of Science, and ProQuest Dissertations & Theses Global from inception to April 2019 with no restrictions on year or language. Study Selection: Teams of 2 reviewers independently screened search results and included prospective cohort studies with 1000 or more participants that reported on the association between dietary patterns and health outcomes. Data Extraction: Two reviewers independently extracted data, assessed risk of bias, and evaluated the certainty of evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria. Data Synthesis: Eligible studies that followed patients for 2 to 34 years revealed low- to very-low-certainty evidence that dietary patterns lower in red and processed meat intake result in very small or possibly small decreases in all-cause mortality, cancer mortality and incidence, cardiovascular mortality, nonfatal coronary heart disease, fatal and nonfatal myocardial infarction, and type 2 diabetes. For all-cause, cancer, and cardiovascular mortality and incidence of some types of cancer, the total sample included more than 400 000 patients; for other outcomes, total samples included 4000 to more than 300 000 patients. Limitation: Observational studies are prone to residual confounding, and these studies provide low- or very-low-certainty evidence according to the GRADE criteria. Conclusion: Low- or very-low-certainty evidence suggests that dietary patterns with less red and processed meat intake may result in very small reductions in adverse cardiometabolic and cancer outcomes.
Article
Full-text available
Background: The selection pressure exercised by antibiotic drugs is an important consideration for the wise stewardship of antimicrobial treatment programs. Treatment decisions are currently based on crude assumptions, and there is an urgent need to develop a more quantitative knowledge base that can enable predictions of the impact of individual antibiotics on the human gut microbiome and resistome. Results: Using shotgun metagenomics, we quantified changes in the gut microbiome in two cohorts of hematological patients receiving prophylactic antibiotics; one cohort was treated with ciprofloxacin in a hospital in Tübingen and the other with cotrimoxazole in a hospital in Cologne. Analyzing this rich longitudinal dataset, we found that gut microbiome diversity was reduced in both treatment cohorts to a similar extent, while effects on the gut resistome differed. We observed a sharp increase in the relative abundance of sulfonamide antibiotic resistance genes (ARGs) by 148.1% per cumulative defined daily dose of cotrimoxazole in the Cologne cohort, but not in the Tübingen cohort treated with ciprofloxacin. Through multivariate modeling, we found that factors such as individual baseline microbiome, resistome, and plasmid diversity; liver/kidney function; and concurrent medication, especially virostatic agents, influence resistome alterations. Strikingly, we observed different effects on the plasmidome in the two treatment groups. There was a substantial increase in the abundance of ARG-carrying plasmids in the cohort treated with cotrimoxazole, but not in the cohort treated with ciprofloxacin, indicating that cotrimoxazole might contribute more efficiently to the spread of resistance. Conclusions: Our study represents a step forward in developing the capability to predict the effect of individual antimicrobials on the human microbiome and resistome. Our results indicate that to achieve this, integration of the individual baseline microbiome, resistome, and mobilome status as well as additional individual patient factors will be required. Such personalized predictions may in the future increase patient safety and reduce the spread of resistance. Trial registration: ClinicalTrials.gov, NCT02058888 . Registered February 10 2014.
Article
Full-text available
Correlating cultural, technological and ecological aspects of both Upper pleistocene modern humans (UpMHs) and Neandertals provides a useful approach for achieving robust predictions about what makes us human. Here we present ecological information for a period of special relevance in human evolution, the time of replacement of Neandertals by modern humans during the Late pleistocene in europe. Using the stable isotopic approach, we shed light on aspects of diet and mobility of the late Neandertals and UpMHs from the cave sites of the troisième caverne of Goyet and spy in Belgium. We demonstrate that their diet was essentially similar, relying on the same terrestrial herbivores, whereas mobility strategies indicate considerable differences between Neandertal groups, as well as in comparison to UpMHs. our results indicate that UpMHs exploited their environment to a greater extent than Neandertals and support the hypothesis that UpMHs had a substantial impact not only on the population dynamics of large mammals but also on the whole structure of the ecosystem since their initial arrival in europe. Nowadays modern humans (Homo sapiens) are the only species of humans left on Earth. This was different during the Late Pleistocene when Neandertals and Upper Pleistocene modern humans (UPMH) coexisted in Europe. Relatively soon after the arrival of UPMHs in this region about 45-43,000 years ago, the Neandertals became extinct 1-4. Differences in the ecological niches of UPMHs and Neandertals while coexisting in the same ecosystems are regularly suggested as being the possible cause for the demise of Neandertals. Emphasis is placed on late Neandertals being ecologically less flexible than UPMHs (but see 5-7) and therefore giving an advantage to UPMHs. According to this hypothesis, UPMHs had a broader dietary ecological spectrum, especially having
Article
Full-text available
Purpose of Review To critically review recent (past 3 years) literature on the definition, diagnosis, and management of small intestinal bacterial overgrowth (SIBO). Recent Findings While various series continue to illustrate the occurrence of SIBO in disease states where well-known risk factors for its occurrence are present (hypochlorhydria, disorders of intestinal structure or motor function, pancreatic insufficiency, and chronic liver disease, for example), the current challenge is in defining the limits of SIBO. Is SIBO truly common among those with “functional” gastrointestinal symptoms where there is no evidence of maldigestion or malabsorption; the original hallmarks of SIBO? Our attempts to address this question continue to be hampered by the limitations of our diagnostic tool kit. There is hope—the application of modern molecular techniques to the study of the small intestinal microbiome, together with some innovative sampling techniques, such as real-time intestinal gas sampling, may soon allow us to truly define the spectrum of SIBO. Summary SIBO, once removed from its original confines as a cause of malabsorption syndrome, has proven to be an elusive and moving target. Only the most rigorous studies employing validated methodologies will finally corral this mysterious entity.
Article
Full-text available
Proboscideans and humans have shared habitats across the Old and New Worlds for hundreds of thousands of years. Proboscideans were included in the human diet starting from the Lower Paleolithic period and until the final stages of the Pleistocene. However, the question of how prehistoric people acquired proboscideans remains unresolved. Moreover, the effect of proboscidean hunting on the eventual extinction of these mega-herbivores was never seriously evaluated, probably because of the lack of acquaintance with the plethora of information available regarding proboscidean hunting by humans. The aim of this paper is to bridge this gap and bring to light the data available in order to estimate the extent and procedures of elephant and mammoth hunting by humans during the Quaternary. This study examines the archaeological evidence of proboscidean hunting during Paleolithic times, and provides a review of ethnographic and ethno-historical accounts, demonstrating a wide range of traditional elephant-hunting strategies. We also discuss the rituals accompanying elephant hunting among contemporary hunter-gatherers, further stressing the importance of elephants among hunter-gatherers. Based on the gathered data, we suggest that early humans possessed the necessary abilities to actively and regularly hunt proboscideans; and performed this unique and challenging task at will.
Article
Description Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even non-gastrointestinal complaints and is increasingly implicated, in lay press and media in the causation of a diverse array of disorders. Its definition, however, remains controversial and true prevalence, accordingly, undefined. The purpose of this review, therefore, was to provide a historical background to the concept of SIBO, critically review current concepts of SIBO (including symptomatology, pathophysiology, clinical consequences, diagnosis and treatment), define unanswered questions and provide a road map towards their resolution. Methods Best Practice Advice (BPA) statements were developed following discussion by the three authors. EMMQ and MP each developed text around certain BPAs based upon a review of available literature. A complete draft was reviewed by all three authors and following discussion, re-drafting and further review and revision a final draft was agreed upon by all authors. Best Practice Advice Statements The definition of SIBO as a clinical entity lacks precision and consistency; it is a term generally applied to a clinical disorder where symptoms, clinical signs and/or laboratory abnormalities are attributed to changes in the numbers of bacteria or in the composition of the bacterial population in the small intestine. Symptoms traditionally linked to SIBO include bloating, diarrhea and abdominal pain/discomfort. Steatorrhea may be seen in more severe cases. There is insufficient evidence to support the use of inflammatory markers such as fecal calprotectin to detect SIBO. Lab findings can include elevated folate and, less commonly, vitamin B12 deficiency, or other nutritional deficiencies. A major impediment to our ability to accurately define SIBO is our limited understanding of normal small intestinal microbial populations– progress in sampling technology and techniques to enumerate bacterial populations and their metabolic products should provide much needed clarity. Controversy remains concerning the role of SIBO in the pathogenesis of common functional symptoms such as those regarded as components of irritable bowel syndrome (IBS). Management should focus on the identification and correction (where possible) of underlying causes, correction of nutritional deficiencies and the administration of antibiotics. This is especially important for patients with significant maldigestion and malabsorption. While IBS has been shown to respond to therapy with a poorly absorbed antibiotic, the role of SIBO or its eradication in the genesis of this response warrants further confirmation in randomized controlled trials. There is a limited database to guide the clinician in developing antibiotic strategies for SIBO, in any context. Therapy remains, for the most part, empiric but must be ever mindful of the potential risks of long-term broad-spectrum antibiotic therapy.
Article
Small intestinal bacterial overgrowth (SIBO) is a common, yet underrecognized, problem. Its prevalence is unknown because SIBO requires diagnostic testing. Although abdominal bloating, gas, distension, and diarrhea are common symptoms, they do not predict positive diagnosis. Predisposing factors include proton-pump inhibitors, opioids, gastric bypass, colectomy, and dysmotility. Small bowel aspirate/culture with growth of 10-10 cfu/mL is generally accepted as the "best diagnostic method," but it is invasive. Glucose or lactulose breath testing is noninvasive but an indirect method that requires further standardization and validation for SIBO. Treatment, usually with antibiotics, aims to provide symptom relief through eradication of bacteria in the small intestine. Limited numbers of controlled studies have shown systemic antibiotics (norfloxacin and metronidazole) to be efficacious. However, 15 studies have shown rifaximin, a nonsystemic antibiotic, to be effective against SIBO and well tolerated. Through improved awareness and scientific rigor, the SIBO landscape is poised for transformation.
Context: Small intestinal bacterial overgrowth (SIBO) has gained popularity on the internet in addition to certain clinical and research circles. This interest has expanded awareness of important new dietary, nutraceutical, and pharmaceutical treatments in addition to laboratory evaluation assessment options. Concomitantly, there appears a loss of parsimony regarding how to use these tools resulting in an untenable degree of testing and treatment for this condition. Objectives: A balanced review of the data regarding SIBO testing, treatment, and management with the goal of establishing non-biased best practices. Design: Non-systematic review. Results: The results for the review fall into two categories. Ineffective Action: Treat only SIBO labs; Treat for SIBO if no symptoms are exhibited; Recommending eating or avoiding foods because they might be good or bad for SIBO; Recommending treatments that are non-validated. Effective Action: Use SIBO breath results, in addition to history and current symptoms, to determine the best treatment; Find foods that work for patients based on dietary elimination and reintroduction; Apply validated treatment for SIBO and IBS in a logical 'step-up' like treatment approach. Conclusions: Testing and treating for SIBO can offer patients clinically significant relief. However, these tests and treatments must be applied with circumspection to prevent over-testing, over-treatment, squandering resources, or creating a fear around certain foods.